Clinical Trial Update: Women's Estrogen/Progestin Lipid Lowering Hormone Atherosclerosis Regression Trial (WELL-HART) [Phase 3]

View source ↗

Summary

A phase 3 clinical trial (WELL-HART) evaluating estrogen/progestin therapy for lipid lowering and regression of atherosclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Cardiovascular Disease
• Coronary Artery Disease
• Ischemic Heart Disease

Drugs mentioned

• Estrogen/progestin combination therapy (Estrogen and progestin)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Cardiovascular Diseases, Coronary Disease | Phase 3 | Status: COMPLETED